October 1, 2021 | Lucid Group, Medical Communications, healthcare communications

Professor Andy Black, an experienced board-level executive for the life sciences industry, has joined Lucid Group as non-executive Chairman of the Board.
Professor Black, co-founder of Kinapse − an international consultancy to the life sciences industry and the winner of six Fast Track awards − is a Professor of Practice at King’s College London, where he teaches entrepreneurship and supports both the university and King’s Health Partners with commercial partnerships.
Professor Black’s extensive pharmaceutical and management experience will help inform Lucid Group’s growth and development strategy, advancing the group towards its vision of bringing together industry-leading capabilities to tackle some of the most challenging healthcare problems through an outcomes-led approach.
Dennis O’Brien, Co-founder and CEO, Lucid Group, commented: “We are delighted to welcome Andy to the Lucid Group as Chairman. His deep industry knowledge, people focus and experience building a strategic consultancy business, make him invaluable in supporting our global development and growth. He is deeply passionate about making a difference to people’s lives which is directly aligned to the Lucid vision.”
Andy Black, Chairman of the Board, Lucid Group, commented: “I am delighted to be taking on the position of Chairman of the Board at Lucid Group. We share the same values and passion for attracting, developing, and retaining the best people to fuel a purpose-driven organisation. I look forward to working closely with our great team as it continues to build the world’s best healthcare solutions business and transform patients’ lives around the world.”
For further information about Lucid Group please visit www.wearelucidgroup.com or contact Laura Gaskell via email: laura.gaskell@wearelucidgroup.com or call +44 7557 739 059.
About Lucid Group
Founded in 2007, Lucid Group is a global multi-capability healthcare communications consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics. We partner with the pharma and biotech industry, delivering life transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. Transforming lives. Always.
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid...
Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced...
In April’s PME, Danny Buckland has been talking to industry leaders about launch excellence in the featured article, Listen, learn and lift off.Buckland points out that pandemic storms have changed the...
In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines...
Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...
In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...
In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...
Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. The global rare disease community and its supporters come together on...
I began as a medical writer after almost a decade working in medical publishing as a production editor. Whilst working in publishing, I was exposed to lots of different writing...
